{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:31:14Z","timestamp":1785598274919,"version":"3.56.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5986-5","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T09:42:11Z","timestamp":1565170931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla\u00ae, T-DM1) administration: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Chung Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Kyung","family":"Choung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang","family":"In Khwarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"issue":"1","key":"5986_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/IOP.0000000000000745","volume":"33","author":"C Mansur","year":"2017","unstructured":"Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular stenosis, and nasolacrimal duct obstruction. Ophthal Plast Reconstr Surg. 2017;33(1):9\u201312.","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"19","key":"5986_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"16","key":"5986_CR3","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","volume":"28","author":"IE Krop","year":"2010","unstructured":"Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698\u2013704.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5986_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5986_CR5","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/ICO.0000000000000868","volume":"35","author":"M Tsuda","year":"2016","unstructured":"Tsuda M, Takano Y, Shigeyasu C, Imoto S, Yamada M. Abnormal corneal lesions induced by Trastuzumab Emtansine: an antibody-drug conjugate for breast Cancer. Cornea. 2016;35(10):1378\u201380.","journal-title":"Cornea"},{"issue":"4","key":"5986_CR6","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clbc.2018.03.005","volume":"18","author":"EO Kreps","year":"2018","unstructured":"Kreps EO, Derveaux T, Denys H. Corneal changes in Trastuzumab Emtansine treatment. Clin Breast Cancer. 2018;18(4):e427\u20139.","journal-title":"Clin Breast Cancer"},{"issue":"20","key":"5986_CR7","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437\u201347.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5986_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/molecules22081281","volume":"22","author":"Hao Chen","year":"2017","unstructured":"Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22(8):E1281.","journal-title":"Molecules"},{"issue":"3","key":"5986_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/cncr.11527","volume":"98","author":"B Esmaeli","year":"2003","unstructured":"Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98(3):504\u20137.","journal-title":"Cancer"},{"issue":"4","key":"5986_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.IOP.0000075016.29682.E0","volume":"19","author":"B Esmaeli","year":"2003","unstructured":"Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg. 2003;19(4):305\u20138.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"5986_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ajoc.2016.11.003","volume":"5","author":"IA Park","year":"2017","unstructured":"Park IA, Sa HS, Chung YS, Cho KJ. Androgen receptor-positive ductal adenocarcinoma of the nasolacrimal duct: a case report. Am J Ophthalmol Case Rep. 2017;5:33\u20137.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"5986_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fonc.2015.00010","volume":"5","author":"E Vagia","year":"2015","unstructured":"Vagia E, Economopoulou P, Oikonomopoulos N, Athanasiadis I, Dimitriadis G, Psyrri A. Androgen-receptor positive lacrimal sac adenocarcinoma demonstrating long-lasting response to LHRH analog plus Abiraterone treatment. Front Oncol. 2015;5:10.","journal-title":"Front Oncol"},{"issue":"5","key":"5986_CR13","first-page":"298","volume":"29","author":"LM Heindl","year":"2010","unstructured":"Heindl LM, Junemann AG, Kruse FE, Holbach LM. Tumors of the lacrimal drainage system. Orbit (Amsterdam, Netherlands). 2010;29(5):298\u2013306.","journal-title":"Orbit (Amsterdam, Netherlands)"},{"issue":"12","key":"5986_CR14","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024\u201331.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5986_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/bjo.46.1.27","volume":"46","author":"Y Dayal","year":"1962","unstructured":"Dayal Y. Corticosteroids and FIBROLYSIN in the prevention of lacrimal duct obstruction. Br J Ophthalmol. 1962;46(1):27\u201330.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"5986_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S0161-6420(86)33620-0","volume":"93","author":"JV Linberg","year":"1986","unstructured":"Linberg JV, McCormick SA. Primary acquired nasolacrimal duct obstruction. A clinicopathologic report and biopsy technique. Ophthalmology. 1986;93(8):1055\u201363.","journal-title":"Ophthalmology"},{"issue":"10","key":"5986_CR17","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3341\/jkos.2014.55.10.1418","volume":"55","author":"YD Kim","year":"2014","unstructured":"Kim YD, Kim NJ, Choung HK, Khwarg SI. The effectiveness of topical steroid instillation in patients with recently developed nasolacrimal drainage stenosis. J Korean Ophthalmol Soc. 2014;55(10):1418\u201325.","journal-title":"J Korean Ophthalmol Soc"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5986-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5986-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T23:12:03Z","timestamp":1596582723000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5986-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5986"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5986-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"2 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for this case report was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"774"}}